Navigation Links
Cystic Fibrosis Axentis Pharma Initiates Clinical Trial for Lung Infections
Date:9/4/2008

ever, we are already in a position to initiate clinical trials to fully assess its safety and tolerability and gather information on appropriate doses. I am very pleased for patients suffering from cystic fibrosis, who will benefit directly from this promising once-a-day treatment: a significant improvement both in treatment and patient management. This is also great news for our investors, who have helped us to advance so far in a very short time."

Fluidosome(R) technology is based on the well characterised drug tobramycin. Utilising synthetic liposomes containing tobramycin, a standard nebulizer delivers the drug directly to the endobronchial sites of infection in cystic fibrosis patients. This results in prolonged, high local drug concentration, which in turn achieves higher efficacy and enables lower doses.

The phase II study will be carried out in 4 international centres. A total of 24 patients will receive treatment: Eight will receive a twice-daily 300 mg dose of the current tobramycin formulation over 28 days; another eight will be given a twice-daily 150 mg dose of Fluidosome(R) over two weeks and later a third group will receive one 300 mg dose of Fluidosome(R) per day for two weeks.

The company has also announced the appointment of two renowned experts to its Scientific Advisory Board. Prof. Adriano Aguzzi, Director of the Institute of Neuropathology at University Hospital Zurich, Switzerland and Prof. Gergely C. Lukacs, Canada Research Chair, Department of Physiology at McGill University Montreal, Canada will in future advise Axentis Pharma on scientific and medical issues related to the company's product pipeline.

Dr. Schreier on the latest additions to the team: "Axentis Pharma is very happy to have such outstanding experts on its Scientific Advisory Board. Just as our investors provide us with the trust and financial means that are essential to the ongoing development of our products, Prof. Aguzzi and Prof. Lukacs will cont
'/>"/>

SOURCE Axentis Pharma AG
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Promising Cystic Fibrosis Compound on Track for Development
2. Symbollon Pharmaceuticals, Inc. Evaluates the Clinical Effects of IoGen(TM) on Fibrocystic Breast Disease
3. Pediatric Pulmonary Expert Comments on Study of Lung Transplants for Cystic Fibrosis
4. Cystic Fibrosis Foundation Reports Upward Trend for Key Health Outcomes
5. Cystic Fibrosis Foundation Announces Positive Early Results for Phase 2 Clinical Trial of VX-770 - an Oral Compound to Treat CF
6. Lung Transplants in Cystic Fibrosis Patients With Life-Threatening Bacteria Sparks Debate at ISHLT Meeting
7. PTC Therapeutics Announces Data Supporting Cough Frequency as a New Outcome Measure in Evaluating Treatments for Cystic Fibrosis
8. PTC Therapeutics Announces Data from Additional Clinical Studies of PTC124 in Cystic Fibrosis Confirming Activity
9. Transave Announces Positive Phase II Results for Once-Daily Arikace(TM) in the Treatment of Cystic Fibrosis Patients Who Have Pseudomonas Lung Infections
10. Mpex Initiates a Phase 2 Clinical Trial of Aerosol MP-376 in the Treatment of Chronic Bacterial Infections in Cystic Fibrosis Patients
11. The Ocean Becomes a Pipeline To A Cure for Cystic Fibrosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2009)... -- Reportlinker.com announces that a new ... its catalogue: ,, Systemic Lupus ... Market Forecasts to 2015 ,, ... Lupus Erythematosus - Drug Pipeline Analysis ... Summary ,, GlobalData, the ...
(Date:12/15/2009)... December 15 EnzySurge Ltd.,(EnzySurge), a ... chronic,wound management market, announced today that it ... Drug Administration (FDA) to market its new,SilverStream(TM) ... cleared,DermaSept, an Over-the-Counter version of the SilverStream ... is the developer of the DermaStream(R) product ...
(Date:12/15/2009)... 15 NxStage Medical, Inc. (Nasdaq: ... products, today announced that a group of its ... embarking on a week-long, conventional (non-dialysis) Caribbean cruise ... cruise, dubbed the "2010 Freedom Cruise: We,re Taking ... on January 3, 2010 and returns on January ...
Breaking Medicine Technology:Reportlinker Adds Systemic Lupus Erythematosus - Drug Pipeline Analysis and Market Forecasts to 2015 2Reportlinker Adds Systemic Lupus Erythematosus - Drug Pipeline Analysis and Market Forecasts to 2015 3Reportlinker Adds Systemic Lupus Erythematosus - Drug Pipeline Analysis and Market Forecasts to 2015 4Reportlinker Adds Systemic Lupus Erythematosus - Drug Pipeline Analysis and Market Forecasts to 2015 5Reportlinker Adds Systemic Lupus Erythematosus - Drug Pipeline Analysis and Market Forecasts to 2015 6Reportlinker Adds Systemic Lupus Erythematosus - Drug Pipeline Analysis and Market Forecasts to 2015 7Reportlinker Adds Systemic Lupus Erythematosus - Drug Pipeline Analysis and Market Forecasts to 2015 8EnzySurge Receives FDA Approval for SilverStream(TM) Innovative Wound Management Solution 2Group of NxStage(R) Home Hemodialysis Patients to Take Caribbean Cruise with the System One(TM) 2Group of NxStage(R) Home Hemodialysis Patients to Take Caribbean Cruise with the System One(TM) 3Group of NxStage(R) Home Hemodialysis Patients to Take Caribbean Cruise with the System One(TM) 4Air Methods Reports 3Q2009 Results and 4Q2009 Update 6031 1Air Methods Reports 3Q2009 Results and 4Q2009 Update 6031 2Air Methods Reports 3Q2009 Results and 4Q2009 Update 6031 3Air Methods Reports 3Q2009 Results and 4Q2009 Update 6031 4Air Methods Reports 3Q2009 Results and 4Q2009 Update 6031 5Air Methods Reports 3Q2009 Results and 4Q2009 Update 6031 6Air Methods Reports 3Q2009 Results and 4Q2009 Update 6031 7InterMune Reports Third Quarter 2009 Financial Results and Business Highlights 6027 1InterMune Reports Third Quarter 2009 Financial Results and Business Highlights 6027 2InterMune Reports Third Quarter 2009 Financial Results and Business Highlights 6027 3InterMune Reports Third Quarter 2009 Financial Results and Business Highlights 6027 4InterMune Reports Third Quarter 2009 Financial Results and Business Highlights 6027 5InterMune Reports Third Quarter 2009 Financial Results and Business Highlights 6027 6InterMune Reports Third Quarter 2009 Financial Results and Business Highlights 6027 7InterMune Reports Third Quarter 2009 Financial Results and Business Highlights 6027 8InterMune Reports Third Quarter 2009 Financial Results and Business Highlights 6027 9InterMune Reports Third Quarter 2009 Financial Results and Business Highlights 6027 10InterMune Reports Third Quarter 2009 Financial Results and Business Highlights 6027 11InterMune Reports Third Quarter 2009 Financial Results and Business Highlights 6027 12InterMune Reports Third Quarter 2009 Financial Results and Business Highlights 6027 13PDI Reports 2009 Third Quarter Financial Results 6023 1PDI Reports 2009 Third Quarter Financial Results 6023 2PDI Reports 2009 Third Quarter Financial Results 6023 3PDI Reports 2009 Third Quarter Financial Results 6023 4PDI Reports 2009 Third Quarter Financial Results 6023 5PDI Reports 2009 Third Quarter Financial Results 6023 6PDI Reports 2009 Third Quarter Financial Results 6023 7PDI Reports 2009 Third Quarter Financial Results 6023 8PDI Reports 2009 Third Quarter Financial Results 6023 9PDI Reports 2009 Third Quarter Financial Results 6023 10PDI Reports 2009 Third Quarter Financial Results 6023 11
... BALTIMORE, Dec. 10 Data by Dr. J. Bart Classen ... Research & Reviews provides further evidence that epidemics of ... to immunization. Classen previously published proof vaccines are causing an ... , The new data as well ...
... results from a Phase 1/2 study of perifosine in ... relapsed from or refractory to bortezomib , ... Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX ) today ... in combination with bortezomib (+/- dexamethasone) in patients with ...
Other Medicine Technology:Epidemics of Both Type 1 Diabetes (Insulin Dependent) and Type 2 Diabetes (Obesity Related) Are Linked to Immunization 2Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology 2Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology 3Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology 4Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology 5Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology 6Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology 7
(Date:12/15/2009)... infectious HIV-1 is widely thought to be the major ... persons. U.S. Military HIV Research Program (MHRP) researchers, however, ... particles can bind to the surface of red blood ... donors. The results were published today in PLoS ... The lead investigators, Dr. Zoltan Beck and Dr. Carl ...
(Date:12/15/2009)... how to make an AIDS vaccine have found the ... the immune system can indeed produce cells with the ... the same time, the immune system works equally hard ... have a chance to mature. , "These studies show ... disease is under the control of immunological tolerance," said ...
(Date:12/15/2009)... users to control the volume without compromising sound-quality or comfort. ... ... 15, 2009 -- EarPeace ( www.earpeace.com ) is redefining hearing ... in three different skin-tone colors. "As a big fan of ... I was looking for a way to continue my active ...
(Date:12/15/2009)... Management Systems (HRMS), announced in a direct response to demand ... (APSS) to its suite of HR software, to increase productivity ... ... Mahwah, NJ (PRWEB) December 15th 2009 -- Humanic ... announced in a direct response to demand for increased technology ...
(Date:12/15/2009)... Better mental health care still needed for those with ... News) -- Suicides among people in Switzerland who were ... the introduction of highly active antiretroviral therapy in 1996, ... that causes AIDS. , Yet despite the decrease, the ... higher than that of the general population, according to ...
Breaking Medicine News(10 mins):Health News:Biological catch-22 prevents induction of antibodies that block HIV 2Health News:EarPeace Introduces Elegant, High-fidelity Hearing Protection Solution 2Health News:Humanic Design is Pleased to Announce Application Self Service (APSS) to its Product Suite to Empower Organizations with Automation 2Health News:HIV Therapy Linked to Fewer Suicides 2
... 50 are more likely to die from suicide than any ... ,A study of public hospital emergency departments in Perth ... the emergency departments of seven Perth hospitals between June 2000 ... suicide within weeks of being discharged. The sample included terminally ...
... organisms, are exposed to ever-changing environments, oxidative stress, ... to defend themselves against all these insults, gain ... simply by ‘stealing’ genetic information from other better-adapted ... sex, known as horizontal gene transfer. ...
... Central Bureau of Investigation (CBI) carried out simultaneous raids ... Delhi and three other cities on Monday.// ,The ... the national capital, an official of the investigating agency ... Safdarjung Hospital's gynaecology department, and Uma Goel of Sucheta ...
... can cure tumors in animals and humans.,Scientists led by Moira ... an aggressive //form of brain cancer after finding the method ... of the herpes virus was injected into the patient who ... But, eight years later he is still alive and his ...
... Hospitals Group plans to invest Rs 350 crore to add ... new addition of 1800 beds, Apollo Group's total capacity would ... ,"There is a plan for adding 800 beds through management ... Hospitals Group Director Finance, Suneeta Reddy, said here on the ...
... that can lead to a multitude of complications if ... suggests the possibility of using tea as a form ... has been found to prevent the incidence of cataracts, ... diabetics worldwide. , ,Researchers developed special rats with ...
Other Medicine News:Health News:Bacteria Evolve Armamentarium Against Antibiotics By ‘Stealing’ Gen 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: